Skip to main content Back to Top
Advertisement

3/29/2024

Dopamine Hydrochloride Injection

Products Affected - Description

    • Dopamine Hydrochloride in 5% Dextrose injection, Baxter, 200 mg/250 mL, Viaflex Plus Plastic container 18 count, NDC 00338-1005-02
    • Dopamine Hydrochloride in 5% Dextrose injection, Baxter, 400 mg/250 mL, Viaflex Plus Plastic container 18 count, NDC 00338-1007-02
    • Dopamine Hydrochloride in 5% Dextrose injection, Baxter, 400 mg/500 mL, Viaflex Plus Plastic container 12 count, NDC 00338-1005-03
    • Dopamine Hydrochloride in 5% Dextrose injection, Baxter, 800 mg/250 mL, Viaflex Plus Plastic container 18 count, NDC 00338-1009-02
    • Dopamine Hydrochloride in 5% Dextrose injection, Baxter, 800 mg/500 mL, Viaflex Plus Plastic container 12 count, NDC 00338-1007-03
    • Dopamine Hydrochloride in 5% Dextrose injection, Pfizer, 400 mg/250 mL, LifeCare flexible container 12 count, NDC 00409-7809-22
    • Dopamine Hydrochloride in 5% Dextrose injection, Pfizer, 800 mg/250 mL, LifeCare flexible container 12 count, NDC 00409-7810-22
    • Dopamine Hydrochloride in 5% Dextrose injection, Pfizer, 800 mg/500 mL, LifeCare flexible container 12 count, NDC 00409-7809-24

Reason for the Shortage

    • Baxter has dopamine on a protective allocation due to potential for increased demand.
    • Hikma has dopamine injection available.
    • Pfizer has dopamine on shortage due to manufacturing delays.

Available Products

    • Dopamine Hydrochloride injection, Hikma, 40 mg/mL, 10 mL vial, 25 count, NDC 00143-9254-25
    • Dopamine Hydrochloride injection, Hikma, 40 mg/mL, 5 mL vial, 25 count, NDC 00143-9252-25
    • Dopamine Hydrochloride injection, Pfizer, 40 mg/mL, 10 mL vial, 25 count, NDC 00409-9104-20
    • Dopamine Hydrochloride injection, Pfizer, 40 mg/mL, 5 mL vial, 25 count, NDC 00409-5820-01

Estimated Resupply Dates

    • Baxter has all presentations on a protective allocation.
    • Hikma has short-dated dopamine 40 mg/mL 10 mL vials available with an expiration date of March 2025.
    • Pfizer has dopamine 400 mg/250 mL premixed bags on back order and the company estimates a release date of April 2024. The 800 mg/250 mL premixed bags are on back order and the company estimates a release date of July 2024. The 800 mg/500 mL premixed bags are on back order and the company estimates a release date of June 2024.

Implications for Patient Care

    • Dopamine is a natural catecholamine that at higher doses (5-15 mcg/kg/min) exhibits inotropic effects and increased cardiac output for patients hemodynamically unstable (eg, cardiogenic shock).[1-3]

Safety

    • Premixed bags and vial strength may differ than our standard concentrations. Ensure proper dosing/rate of administration if non-standard concentration is used.¯¯

Alternative Agents & Management

    • For states of hemodynamic instability, use alternative catecholamine or non-catecholamine inotropes and vasopressors.[4]
    • Information on assessing the management of different types of cardiogenic shock can be found at https://www.ahajournals.org/doi/10.1161/CIR.0000000000000525#d1e1478. Table 5 serves as a good reference for which vasoactive agents to use in specific causes/presentations of cardiogenic shock.[4]
    • The American College of Cardiology created a guidance of recommendations for the DOBUTamine shortage (another inotropic agent). Table 1 provides a summary of pharmacological properties of all vasopressors and inotropes that can also be utilized to assess alterative agents for DOPamine. This information can be found here: https://www.acc.org/Latest-in-Cardiology/Articles/2022/08/02/12/42/What-You-Need-to-Know-Guidance-For-Clinicians-on-Dobutamine-Shortage

References

    1. Dopamine HCl in 5% Dextorse injection [prescribing information]. Mukilteo, WA: HF Acquisition Co LLC; February 2023.
    2. Dopamine HCL injection [prescribing information]. Lake Forest, IL: Hospira Inc; September 2023.
    3. Dopamine. Lexicomp Online, Lexi-Drugs. UpToDate, Inc, Waltham, MA; 2023.¯
    4. van Diepen S, Katz JN, Albert NM, et al. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525

Updated

Updated March 29, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 9, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT